Member Info for researcher1

good to have some plain speaking - so I wonder what became of Erik's "exponential growth" of internet sales? UK market a key indicator in the months following CE - everything ready to roll - let's hope they stick to timescales...

can't make it Mik - would like to look them in the face whilst complaining - you?

don't listen to TW - this is succeeding despite him.... and "hard to please" is a crazy thing to say about him - try FOX, CPT, NIPT, SGB - all tipped at more than twice their current SP (and the last at 25 times current SP). He gives good tips for companies who pay him to attend his investor show, so has no clear insight at all. Avoid at all costs and don't pay attention to his recommendations. There is an investor group that I was invited to join who simply back against ('short') his tips 3 days after he has made them.

agreed about the revenue, though some of the deals make a steep increase inevitable - but obviously I should have said IMO with the price prediction!

please don't mention TW, the worst punter bar non. Opti is a success story for him, behind which lie 20 dogs that he's bought, pumped and watched crash (try Stanley Gibbons for starters - he tipped them at over £1 and then doubled down with their fundraise at 10p - now 4p! BEWARE!). He also advised said Sell OPTI at 54p (before he panicked and jumped back in around 70p).

Anyway, thankfully we are in one of his exceptions. Back of an envelope revenue expectations put the SP in a year at around 260p - however remember some of us still have shares from the 8p days, so there will be some rockiness - definitely a share to hold a large core of, but also to trade on CDF if you can - it's a money printing machine!

yes, that's true, but as there's a lot of research money being poured into solving those problems, I can see investors sitting on their hands until the picture becomes clearer...

it may well be me being ultra cautious, but advances in lithium extraction from brine open up many other resources that don't require the same levels of investment. I personally feel Sonara is viable, but I can now imagine large investors staying away.

I've been in and out of BCN over the past two years but sold at 98 when it moved onto AIM. Feel sorry for all LTH at the moment, but not tempted back yet - too much research emerging about cheaper methods of getting at Lithium, so for the first time I can envisage the possibility of Sonara not being developed.

ha, so instead they bring the Ask down! wonder what those who paid 50p for stacks of shares think of that manoeuvre?

MMs surely will have to mark this up soon with the buying pressure today?

an odd parallel, I'd say - but if you must use it then perhaps let's compare MCaps and imagine AGL's SP post-FDA approval being multiplied by 100!

yes I feel we'll see consistent accumulation through September...

more great news - how long can this stay under the radar???

excessive delay, again, but this time they are being outflanked.

it's the same, old song, but with a different meaning...

sing along.

what price??

thanks Bermuda - nothing new but a concise report on Angle's advantage - let's hope the FDA get a move on...!

did you know there's an investor group that shorts his recommendations? Says something!

TW is a crony of anyone desperate enough to take a stand at his investor show - he is by far and away the worst tipper out there, even including Woodford, who he hates (but also loves, as his fund is doing almost as badly as TW's own). Some of his great tips have been: Concepta (as you know) at 18p, Stanley Gibbons at £1, FOX at 20p, OBT, and the list goes on. Once in a while (about 1 in 10) a tip makes him profit - such as OPTI. Even then he advised a sell at 50p before jumping back in when it was clear he'd made a mistake. He's a bit better at shorting, because of the pessimistic and unpleasant person he is, but even then there are glaring errors, where he's blinded by his own right wing prejudice.

probably best to work your way back through the RNS posts on this site Benje - the picture is complex, with multiple deals all having as yet unknown revenues but very high predicted/possible - it's somewhat pointless to throw numbers around but each of the 3 best deals could generate tens of millions annually. The FDA won't be involved.
Bottom line: get some now sub £1 if you can...

yawn